Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xingya Li

Showing results (81-90 of 146) with videos related to

Pageof 15
Sort By:
Cancer Immunology, Immunotherapy : CII|January 5, 2022
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trialJifang Gong, Junning Cao, Qingyuan Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 26, 2024
AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLCShiqi Mao, Xinyu Liu, Lin Wang, et al.
Nature Materials|March 11, 2020
Efficient metal ion sieving in rectifying subnanochannels enabled by metal-organic frameworksJun Lu, Huacheng Zhang, Jue Hou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2020
Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 TrialYun Fan, Jun Zhao, Qiming Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2022
Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion StudyYuankai Shi, Yanqiu Zhao, Sheng Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2021
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 TrialShun Lu, Jie Wang, Yan Yu, et al.
Nature Medicine|August 19, 2025
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trialShaodong Hong, Qiming Wang, Ying Cheng, et al.
JTO Clinical and Research Reports|October 11, 2022
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring <i>MET</i> Exon 14 Skipping AlterationsShun Lu, Jian Fang, Xingya Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2021
Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 StudyXinghao Ai, Qiming Wang, Ying Cheng, et al.
The Lancet. Respiratory Medicine|June 24, 2021
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 studyShun Lu, Jian Fang, Xingya Li, et al.
Pageof 15

Showing results (81-90 of 146) with videos related to

Sort By:
Pageof 15
Cancer Immunology, Immunotherapy : CII|January 5, 2022
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trialJifang Gong, Junning Cao, Qingyuan Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 26, 2024
AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLCShiqi Mao, Xinyu Liu, Lin Wang, et al.
Nature Materials|March 11, 2020
Efficient metal ion sieving in rectifying subnanochannels enabled by metal-organic frameworksJun Lu, Huacheng Zhang, Jue Hou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2020
Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 TrialYun Fan, Jun Zhao, Qiming Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2022
Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion StudyYuankai Shi, Yanqiu Zhao, Sheng Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2021
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 TrialShun Lu, Jie Wang, Yan Yu, et al.
Nature Medicine|August 19, 2025
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trialShaodong Hong, Qiming Wang, Ying Cheng, et al.
JTO Clinical and Research Reports|October 11, 2022
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring <i>MET</i> Exon 14 Skipping AlterationsShun Lu, Jian Fang, Xingya Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2021
Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 StudyXinghao Ai, Qiming Wang, Ying Cheng, et al.
The Lancet. Respiratory Medicine|June 24, 2021
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 studyShun Lu, Jian Fang, Xingya Li, et al.
Pageof 15